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Abstract—Biomaterial vaccines offer cargo protection, tar-
geting, and co-delivery of signals to immune organs such as
lymph nodes (LNs), tissues that coordinate adaptive immu-
nity. Understanding how individual vaccine components
impact immune response has been difﬁcult owing to the
systemic nature of delivery. Direct intra-lymph node (i.LN.)
injection offers a unique opportunity to dissect how the
doses, kinetics, and combinations of signals reaching LNs
inﬂuence the LN environment. Here, i.LN. injection was used
as a tool to study the local and systemic responses to vaccines
comprised of soluble antigen and degradable polymer par-
ticles encapsulating toll-like receptor agonists as adjuvants.
Microparticle vaccines increased antigen presenting cells and
lymphocytes in LNs, enhancing activation of these cells.
Enumeration of antigen-speciﬁc CD8+ T cells in blood
revealed expansion over 7 days, followed by a contraction
period over 1 month as memory developed. Extending this
strategy to conserved mouse and human tumor antigens
resulted in tumor antigen-speciﬁc primary and recall
responses by CD8+ T cells. During challenge with an
aggressive metastatic melanoma model, i.LN. delivery of
depots slowed tumor growth more than a potent human
vaccine adjuvant, demonstrating local treatment of a target
immunological site can promote responses that are potent,
systemic, and antigen-speciﬁc.
Keywords—Lymph node, Vaccine, Adjuvant, Microparti-
cle and nanoparticle, Cancer, Immunotherapy.
INTRODUCTION
Historically vaccine design has focused on generat-
ing potent, speciﬁc immune responses. However,
equally important for vaccines aimed at persistent and
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emerging diseases, is the need to better control the
nature of the immune responses that are generated.
For example, in the context of cancer vaccination,
tumor-speciﬁc CD8+ T cells that exhibit memory-like
characteristics and proliferate at very high rates might
help overcome the immunosuppressive tumor
microenvironment.10,33 Even vaccines aimed at well
controlled pathogens—such as ﬂu—could beneﬁt from
formulations that offer better immunomodulatory
capabilities, in this example, by conferring increased
production of mucosal antibodies.7 Another area of
intense research along these lines is in the exploitation
of new adjuvants—such as toll like receptor agonists
(TLRas) that stimulate pathogen-detecting inﬂamma-
tory pathways. These molecules can be delivered alone,
or in combination to create polarizing or synergistic
effects.6,26,50,51,55 Better understanding of the effects of
speciﬁc vaccine components, adjuvants, and carriers,
along with knowledge of how these agents work to-
gether, would help support the design of more effective
vaccines.
Lymph nodes (LNs) are tissues that initiate, main-
tain, and regulate adaptive immune response, and are
thus critical targets for vaccines and immunotherapies.
At these sites, antigen presenting cells (APCs) display
antigens to T and B cells with the same speciﬁcity to
mount antigen-speciﬁc eﬀector function.14 Thus the
local signals integrated in LNs help deﬁne the speci-
ﬁcity, magnitude, and nature of the resulting systemic
responses. A key hurdle facing new vaccines and
immunotherapies is efﬁciently targeting these sites.30
For example, to effectively prime lymphocytes against
a speciﬁc antigen, both the antigen and an adjuvant or
other stimulatory immune signal need to be localized
to the same tissue, while the combinations and relative
concentrations of vaccine components dramatically
impact the characteristics of this response. Unsurpris-
ingly, signiﬁcant interested has developed in strategies
that allow more efﬁcient delivery to LNs and more
precise control over the local environment in these
tissues.
To address the challenges above, many reports in
the past several decades have investigated biomaterial
carriers (e.g., polymer particles,25,49 liposomes
15,21,32,48) that encapsulate or adsorb combinations of
antigens and adjuvants.2 The tunable sizes, particulate
nature, and ability to co-deliver cargos make these
vehicles attractive as vaccine formulations that can be
injected and drain to LNs or can be carried there by
APCs.18 Particle size plays a major role in the efﬁ-
ciency and route by which these vaccines reach LNs,42
an area that has been heavily investigated.2,18 While
many exciting approaches have been reported, even
those that generate robust immune responses are lim-
ited in the control they provide over the routes or doses
by which particles reach LNs after injection. Instead,
vaccines generally rely on passive draining through
lymphatic vessels, uptake by APCs and subsequent
trafﬁcking to LNs, or more recently, active targeting
using receptor/ligand interactions.2,18 Thus, a rela-
tively small faction of the total injected dose actually
reaches LNs,19,42 increasing the required dose in some
cases, or preventing efﬁcacious response in others.
These effects are also important since some vaccine or
immunotherapy components have toxic or inﬂamma-
tory effects that limit the dose or frequency of
administration.
A consideration speciﬁc to biomaterial carriers is
the growing list of polymers, such as poly(lactic-co-
glycolic acid) (PLGA), polystyrene, and others,2,3,37,47
that exhibit intrinsic inﬂammatory effects even in the
absence of other immune signals.2 PLGA, for example,
is used in countless vaccine and immunotherapy
studies, but can activate the inﬂammasome and
increases stimulatory response to TLRas.47 While these
are characteristics that can be harnessed, they can also
complicate vaccine research because of the increased
complexity resulting from ‘‘carrier-effects’’ that alters
how the immune system responds to antigens or other
vaccine components. A better understanding of how
immune signals—and their biomaterial carriers—in-
teract with the local LN microenvironment, and how
these interactions direct systemic immunity would help
improve vaccine performance, while also contributing
to more rational vaccine design strategies.
We recently developed a strategy to deposit bio-
material vaccine depots directly in LNs of mice using
intra-lymph node (i.LN.) injection.3,4,22 This platform
allows direct control over delivery of vaccine compo-
nents to LNs, and sustained release of encapsulated
cargo within these tissues. In our previous work, we
discovered i.LN. delivery of microparticles (MPs)
encapsulating adjuvant generate more potent
responses than nanoparticles or soluble adjuvant be-
cause these large particles are better retained in LNs.22
Therefore, we sought to use i.LN. injection of adju-
vant-loaded MPs as a tool to study the evolution of
these local and systemic responses over time in mice.
We demonstrate that i.LN. deposition of vaccine de-
pots consisting of PLGA MPs loaded with a TLR3a
and suspended in soluble ovalbumin (OVA) antigen
increases the number of APCs and lymphocytes in LNs
over the course of 7 days. Treatment does not alter the
relative composition of these compartments, but does
increase the activation of resident APCs. A single
treatment with these vaccine depots expands antigen-
speciﬁc CD8+ T cells locally in treated LNs and sys-
temically in peripheral blood, evolving from a potent
effector response at day 7 to a memory response by day
28. We also show this approach is generalizable: i.LN.
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injection of vaccine depots loaded with either PolyIC
or CpG—potent TLRas being explored in human tri-
als—and then mixed with conserved human melanoma
antigens potently expand tumor-speciﬁc CD8+ T cells.
These effects correlate with slowed tumor progression
during an aggressive challenge with metastatic mela-
noma. Together this work demonstrates that local
programming of distinct LNs with adjuvant depots can
be used to drive local alterations that promote immu-
nity that is systemic and antigen-speciﬁc.
MATERIALS AND METHODS
Particle Synthesis
Degradable MPs were synthesized via a double-
emulsion, solvent evaporation technique.4,22 For lipid
stabilized particles, 1,2-dioleoyl-sn-glycero-3-phospho-
choline, 1,2-distearoyl-sn-glycero-3-phosphoethanolam-
ine-N-[amino(polyethylene glycol)-2000], and 1,2-di-
oleoyl-3-trimethylammoniumpropane (Avanti Polar Li-
pids) were prepared at a 60:20:20 mol ratio and dried
under nitrogen. 80 mg of PLGA (Sigma) was dissolved
with the 5.15 lmol of lipids in 5 mL of dichloromethane.
An inner aqueous phase containing 500 lL of water or
5 mg of polyinosinic-polycytidylic acid (PolyIC) (In-
vivogen) in 500 lL of water was added to this organic
phase containingpolymerand lipidand sonicated for 30 s
at 12 W to form the ﬁrst emulsion. This emulsion was
then added to 40 mL of water, homogenized for 3 min at
16,000 rpm, and then allowed to evaporate overnight
while stirring to remove any excess organic solvent. Par-
ticles stabilized with poly(vinyl alcohol) (PVA, Sigma)
were formed as above by removing lipids and replacing
the second water phase with a 2% w/v solution of PVA.
For particles containing CpG (sequence: 5¢ T-C-C-A-T-
G-A-C-G-T-T-C-C-T-G-A-C-G-T-T 3¢, IDT), 3 mg of
CpG in 500 lL of water was used for the ﬁrst aqueous
phase. After overnight stirring, all particle formulations
were passed through a 40 lm cell strainer to remove any
large aggregates and collected via centrifugation
(50009g, 5 min, 4 C). Supernatants were removed and
particleswerewashed three timeswith1 mLofwater then
suspended in water or PBS for animal studies, or lyo-
philized and stored at 4 C prior to use. For preparation
of ﬂuorescently-labeled particles, 5 lL of DiI (Invitro-
gen) was added to the organic phase.
Particle Characterization
Particle diameter was determined using an LA-950
laser diﬀraction analyzer (Horiba). Zeta potential was
measured using a Malvern Zetasizer Nano ZS90.
PolyIC and CpG loading levels were determined via
UV/Vis spectrophotometry after hydrolyzing a known
mass of lyophilized particles overnight in 0.2 M
NaOH. Absorbance values were compared to standard
curves of known concentrations of PolyIC or CpG to
determine a mass of cargo per mass of polymer.
i.LN. Injection
For each animal study, a small region of fur was
removed from the lateral hind quarter of 4–6 week old
C57BL6 mice (The Jackson Laboratory) by shaving the
area and applying a mild depilatory. Tracer dye (Evans
Blue) was then injected subcutaneously (s.c.) on each
side of the tail base as previously reported.3,4,22 After
allowing 16 h for the tracer dye to drain to the inguinal
LNs for visualization, a 31G insulin needle was used to
inject 10 lL containing the indicated treatment into
each inguinal LN. For visualization of particles in LNs,
1 mg of DiI labeled MPs were injected. For model
antigen studies, vaccinations consisted of 1 mg of par-
ticles encapsulating ~8.5 lg PolyIC/mgMPs suspended
in PBS with 25 lg soluble ovalbumin (OVA, Wor-
thington) (‘PolyIC MP/OVA’), an injection of 1 mg of
PLGAMPs with no cargo (‘Empty’), or an injection of
buffer alone (‘sham’), as indicated. In experiments
comparing PolyIC and CpG depots, equivalent doses of
adjuvant encapsulated in MPs were administered i.LN,
after being suspended in PBS with 25 lg of soluble
OVA or soluble Trp2 (SVYDFFVWL, Genscript)
antigens. After priming, mice were boosted with soluble
vaccine treatments s.c. at each side of tail base at day 21,
with each injection consisting of 25 lg antigen
and 25 lg adjuvant. For studies comparing melanoma
antigens (Trp2, hgp100), treatments included 1 mg of
particles containing ~3.5 lg CpG/mgMPs suspended in
PBS with 25 lg of soluble Trp2 (‘CpG MP/Trp2¢) or
soluble hgp100 (KVPRNQDWL, Genscript; ‘CpG
MP/hgp100¢) antigens, or strong pre-clinical vaccine
consisting of 50 lg of CpG and 50 lg peptide formu-
lated with montanide ISA 51 (Seppic; ‘Montanide/
CpG/Trp2¢ or ‘Montanide/CpG/hgp100’). After vacci-
nating i.LN. at day 0, subsequent boosts for MP groups
were given at days 15 and 36 post prime and were
identical to the prime but administered s.c. at the tail
base. For the montanide groups, all injections were s.c.,
but the second boost consisted of soluble Trp2 or sol-
uble hgp100 mixed with CpG (see caption). All animal
studies were approved by the University of Maryland
IACUC and conducted in accordance with local, state,
and federal guidelines.
Tissue Collection, Processing, and Flow Cytometry
At the indicated times after treatment, LNs were
collected from mice, placed in PBS, and processed into
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single cell suspensions by mechanical dissociation
through a 40 lm strainer. Cells were split into three
portions. One portion of cells was centrifuged (8009g,
5 min, 4 C) and suspended in FACS buffer (1 9 PBS
with 1% w/v bovine serum albumin, Sigma) containing
1% DAPI (Invitrogen) and Liquid Counting Beads
(BD) to quantify cell viability and enumerate total cell
numbers using a FACSCanto II (BD), respectively. The
other two portions of cells were washed once with 1 mL
of FACS buffer then blocked with Fc Block (anti-
CD16/CD32, BD) for 10 min at room temperature to
inhibit any non-speciﬁc binding. After blocking, one
portion of cells was stained for innate cell type and
activation with indicated antibodies against cell surface
markers including CD11c, F4/80, CD40, CD80, CD86,
and I-A/I-E (mouse MHCII). Cells were then washed
twice, suspended in FACS buffer, and quantiﬁed via
ﬂow cytometry. The ﬁnal portion of cells was stained for
lymphocyte populations and antigen-speciﬁc tetramer
levels. First, 25 lL of anti-SIINFEKL tetramer was
added and incubated for 30 min at room temperature.
Then, 25 lL of antibodies against surface markers
including B220, CD3, CD4, and CD8 were added and
incubated for 20 min at room temperature. Cells were
then washed and evaluated, as above. The frequency of
each cell population (percent of parent population) and
number of counted cells per identical acquisition vol-
ume (80 lL) was evaluated. The B220 antibody was
purchased from eBiosciences and all other antibodies
were purchased from BD.
MHC Tetramer Staining of Peripheral Blood
Every 7 days, 100 lL of blood was collected from
mice treated as above via submandibular bleeding. Red
blood cells were removed by adding 1 mL of ACK lysis
buffer to the blood, incubating for 3 min, collecting
cells via centrifugation (8009g, 5 min, 4 C), and
repeating with 1 mL of fresh ACK lysis buffer. After
the second round of ACK lysis buffer, cells were sus-
pended in FACS buffer, blocked with Fc Block, and
stained with a tetramer speciﬁc for either SIINFEKL
(CD8-epitope of OVA), Trp2, or hgp100 for 30 min at
room temperature. All tetramers were purchased from
MBL International. Following incubation, cells were
stained against surface markers CD3, CD8, CD44, and
CD62L for 20 min at room temperature. After wash-
ing twice with FACS buffer, cells were suspended in
FACS buffer containing DAPI and the percentage of
antigen-speciﬁc cytotoxic T cells (DAPI, CD8+, tet-
ramer+) was quantiﬁed via ﬂow cytometry. To deter-
mine generation of central memory T cell phenotypes,
tetramer+ CD8+ cells were gated for CD44high/
CD62Lhigh populations and compared to the percent-
age of effector memory T cells (CD44high/CD62Llow).
Tumor Challenge Studies
In some studies, after treating mice with the indicated
vaccines, mice were administered 300,000 B16-F10 cells
(ATCC) in 100 lLof 19PBS s.c. at the hind ﬂank. Each
day following inoculation, body weight was monitored
and tumor burden was calculated as a product of two
orthogonal diameters. Mice were euthanized according
to IACUC-approved humane endpoints when the
aggregate tumor burden reached 150 mm2.
Immunohistochemical Analysis
At indicated time points, inguinal LNs were removed
and frozen in OCT compound (Tissue-Tek). Using a
Microm HM 550 cryostat (Thermo Fisher Scientiﬁc
Inc.), 6 lm sections of LNs were cut, transferred to
slides, and allowed to dry overnight. LN tissue was then
ﬁxed for 5 min in ice-cold acetone then washed in 19
PBS. Samples were then blocked for non-speciﬁc bind-
ing of secondary antibody using 5% goat and 5% don-
key serum in 19 PBS for 30 min. After washing in PBS,
tissues were stained for cell surface markers including
B220 (eBioscience), CD3 (Abcam), and CD11c (BD) for
1 h at room temperature. After washing twice with PBS,
ﬂuorescent secondary antibodies (Jackson Immunore-
search) were added for 45 min then washed three more
times. After staining, sections were ﬁxed with 4%
paraformaldehyde, washed with PBS, quenched with
1% glycerol in PBS, and washed again before mounting
in Prolong Diamond AntifadeMountant (LifeSciences)
and imaging using an Olympus IX83 ﬂuorescent
microscope. Processing of images was conducted versus
an antibody iso-type control and levels were adjusted
equally for all similar channels.
Statistical Analysis
Student’s t tests were used in comparison of two
groups. One-way ANOVA with a Tukey post-test was
used to compare three or more groups, or two-way
ANOVA for comparisons over time. In all cases,
analyses were carried out with Graphpad Prism (ver-
sion 6.02). Error bars in all panels represent the
mean ± SEM and p values £0.05 were considered
signiﬁcant. Levels of signiﬁcance were deﬁned as
*p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001.
RESULTS
PLGA MPs are Dispersed in LNs Following i.LN.
Injection
PLGA MPs were synthesized via a double-emul-
sion/solvent evaporation technique allowing for the
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inclusion of negatively charged nucleic acid TLRa
adjuvants PolyIC or CpG with loading levels of 8.5 lg/
mg MP or 3.5 lg/mg MP, respectively (Table 1).
Addition of PolyIC led to an increase in particle
diameter from 2.2 to 4.3 lm and a shift in zeta
potential from 24.9 mV to 23.7 mV; replacement of
PolyIC with CpG led to similar shifts (Table 1). To
ﬁrst conﬁrm retention of injected MPs into LNs, we
injected DiI-labeled MPs into inguinal LNs of mice
using the approach we previously described
(Fig. 1a).3,4,22 28 days after injection, LNs were
removed and then stained for B cell (Fig. 1b, cyan) and
T cell zones (Fig. 1b, white). Fluorescent microscopy
conﬁrmed retention of MPs in the LNs at this time
point (Fig. 1b, green).
i.LN. Injection of PolyIC MP/OVA Increases the
Number of APCs and Lymphocytes in LNs
After conﬁrming MPs are retained in LNs of mice
over 4 weeks, we used i.LN. injection to administer a
vaccine of PolyIC MPs mixed with soluble OVA
(PolyIC MP/OVA), or to administer a buffer injection
(sham). Cell viability and the frequency and number of
DCs, macrophages, T cells, and B cells in the treated
nodes were then monitored over 1 week using identi-
cally-treated sets of groups. Following treatment,
PolyIC MP/OVA, while slightly diminishing initial cell
viability relative to sham, did not impact viability after
1 week (Fig. 2a). Particles did cause an increase in the
overall number of cells (Fig. 2b), as well as the volume
TABLE 1. Characteristics of adjuvant loaded PLGA-MPs






Empty 2.19 ± 0.14 n/a 24.93 ± 0.91
PolyIC 4.26 ± 0.09 8.53 ± 0.46 23.70 ± 0.71
CpG 4.02 ± 0.14 3.45 ± 0.37 23.23 ± 2.54
FIGURE 2. i.LN. injection of PolyIC MP/OVA depots
increases innate cell numbers in the LNs without affecting cell
viability. (a) Viability and (b) total number of LN cells after i.LN.
injection of PolyIC MP/OVA depots or a sham injection of PBS
at days 1, 3, and 7. (c) Percentage of total LN cells which are
DCs (CD11c+) and macrophages (F4/80+) and (d) number of
DCs and macrophages in LNs counted in an identical acqui-
sition volume (80 lL). n = 9–10 LNs per group with bars
depicting mean 6 SEM. (*p< 0.05; **p< 0.01; ***p<0.001).
FIGURE 1. Vaccine depots can be locally deposited in LNs
via i.LN. injection. (a) Schematic depicting i.LN. injection of
vaccine depots. A tracer dye is injected s.c. at the tail base,
which then drains to the inguinal LNs allowing visualization of
the LN through the skin. Vaccine depots can then be injected
into the LN; (b) Histological section of LN 28 days after i.LN.
injection of fluorescent depots. B cells (B220+, cyan), T cells
(CD3+, white), PLGA MPs (DiI, green). Scale bar = 200 lm.
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of each LN (discussed below), with nodes treated with
PolyIC MP/OVA exhibiting signiﬁcantly more cells
per LN than the sham at day 1 (p< 0.01); a similar
trend was observed over 1 week. In investigating how
PolyIC MP/OVA treatment inﬂuenced innate immune
cell populations, we discovered the frequency of DCs
(CD11c+) did not signiﬁcantly change over 1 week,
while a slight elevation in macrophage (F4/80+) fre-
quency was observed (Fig. 2c). However, the number
of each of these cell types (normalized to equivalent
tissue cell suspensions) increased over time, with sig-
niﬁcantly more DCs (p< 0.001) and macrophages
(p< 0.01) accumulating in the LNs over 7 days fol-
lowing PolyIC MP/OVA injection (Fig. 2d). Similarly,
we observed modest changes in the frequency of lym-
phocytes in the B cell (B220+) and T cell (CD3+;
CD3+/CD4+; CD3+/CD8+) compartments relative
to sham injections (Fig. 3a). However, enumeration of
the number of lymphocytes again revealed PolyIC MP/
OVA increased the number of cells in each population,
with the maximum difference between groups occur-
ring 7 days after the immunization. Immunohisto-
chemical staining of the LNs at 1 day (Fig. 4a) and
7 days (Fig. 4b) after injection conﬁrmed the increased
total number of cells, indicated by the increased area
evident in each section; all sections are presented at the
same scale. These studies also qualitatively conﬁrmed
the increased DC levels we measured in response to
PolyIC MP/OVA treatment relative to sham, and the
increase in DC number as a function of time. These
trends are illustrated in the insets of Fig. 4b at day 7
(i.e., sham vs. PolyIC MP/OVA) and the insets of
Figs. 4a and 4b for PolyIC MP/OVA (i.e., day 1 vs.
day 7), respectively.
PolyIC MP/OVA Treatment Activates LN-Resident
APCs
After determining that i.LN. treatment with PolyIC
MP/OVA increases the number of APCs, we tested if
these populations exhibited an increased activation
state by staining for surface activation markers asso-
ciated with co-stimulation and antigen presentation
(i.e., CD40, CD80, CD86, I–A/I–E). In all cases,
PolyIC MP/OVA caused a signiﬁcant increase in the
number of cells positive for each marker compared to
the sham injected control (Fig. 5a). Interestingly, the
number of activated DCs increased over time with the
FIGURE 3. i.LN. injection of PolyIC MP/OVA depots increases total number of T and B lymphocytes within LNs. (a) Percentages
and (b) total numbers of B cells (B220+), T cells (CD3+) as well as CD4+ T cells (CD3+/CD4+) and CD8+ T cells (CD3+/CD8+) in LNs
after i.LN. injection of PolyIC MP/OVA depots or a sham injection of PBS at days 1, 3, and 7. Numbers are counted in an identical
acquisition volume (80 lL). n = 9–10 LNs per group with bars depicting mean 6 SEM. (*p< 0.05; **p< 0.01; ***p< 0.001;
****p< 0.0001).
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highest levels of each marker occurring 7 days after
treatment (Fig. 5a, red). The macrophage population
exhibited similar activation effects (Fig. 5b). However,
compared to DCs, which showed increases in the
number of cells expressing each marker over time, only
CD40 and I-A/I-E increased as a function of time.
Macrophage expression levels of CD80 and
CD86—while higher than levels in sham-injected
nodes—remained at a near-constant, elevated level
over 1 week.
Local Changes in APC Function Drive Local and
Systemic Antigen-Speciﬁc CD8+ T Cell Response
We next used MHC-I tetramer staining to investi-
gate if the local activation we observed drove genera-
FIGURE 4. Increased LN size and DC numbers in LNs occurs by day 7 after i.LN. injection of PolyIC MP/OVA depots. Histological
staining of LNs for B cells (B220+, cyan), T cells (CD3+, white), and DCs (CD11c+, green) in LNs 1 day (a) and 7 days (b) after i.LN.
injection of PolyIC MP/OVA depots or a sham injection of PBS. Scale bar = 400 lm; 20 lm in inset.
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tion of antigen-speciﬁc T cells, both in treated nodes
and systemically. Analysis of LNs after treatment re-
vealed that vaccinating with PolyIC MP/OVA
increased both the frequency and number of antigen-
speciﬁc CD8+ T cells within the LN (Figs. 6a and 6b).
While the sham injection (Figs. 6a and 6b, blue) re-
mained at a constant, low level, the PolyIC MP/OVA
treated mice exhibited a signiﬁcant (p< 0.01) increase
in SIINFEKL-speciﬁc T cells 7 days after priming. To
investigate how these local changes to the LN
microenvironment impacted systemic changes in anti-
gen-speciﬁc responses, mice were treated with either
PolyIC MP/OVA, empty MPs, a sham injection, or left
untreated. After vaccination on Day 0, blood was
collected weekly and SIINFEKL tetramer staining was
used to determine the percentage of antigen-speciﬁc
CD8+ T cells circulating in peripheral blood. Fig-
ures 6c–6f depicts representative ﬂow cytometry plots
showing the gating scheme applied to samples from
naı¨ve (Fig. 6c, gray), sham (Fig. 6d, blue), empty MP
(Fig. 6e, green), or PolyIC MP/OVA (Fig. 6f, red)
treated mice 7 days after immunization. The average
SIINFEKL tetramer levels revealed that treatment
with PolyIC MP/OVA signiﬁcantly increased
(p< 0.0001) systemic levels of SIINFEKL-speciﬁc
CD8+ T cells 7 days after treatment, followed by a
prototypical contraction period through day 28
(Fig. 6g). The elevated level of SIINFEKL-speciﬁc
CD8+ T cells at day 28 suggested development of
immune memory, which we assessed using common
markers for effector T cells and memory T cells among
CD8+/Tetramer+ cells. These studies revealed a
nearly twofold increase in the percentage of central
memory T cells (CD62Lhigh/CD44high among SIIN-
FEKL-speciﬁc CD8+) and a subsequent decrease in
effector memory phenotypes (CD62Llow/CD44high)
over this same time (Fig. 6h).
To test the robustness and modularity of this plat-
form, we next tested if i.LN. injection expands antigen-
speciﬁc T cells with vaccines containing different
TLRas or other antigens, in particular, Trp2 pep-
tide—a clinically-relevant tumor associated antigen
conserved in murine and human melanoma.38 Depots
were formulated with either PolyIC or CpG—a potent
adjuvant being studied to induce anti-tumor immunity
12,49—and mixed with soluble OVA or Trp2. Mice were
immunized i.LN at day 0 with vaccine depots encap-
sulating identical doses of adjuvant, and then boosted
at day 21 with soluble vaccine components s.c. at the
tail base. At days 7 and 28 (7 days after the prime and
FIGURE 5. PolyIC MP/OVA depots injected i.LN. drive prolonged increase in surface activation marker expression in DCs and
macrophages. Number of DCs (a) and macrophages (b) in LNs expressing activation markers CD40, CD80 CD86 and I-A/I-E at 1, 3,
and 7 days after i.LN. injection of depots. Numbers are counted in an identical acquisition volume (80 lL). n = 9–10 LNs per group
with bars depicting mean 6 SEM. (*p< 0.05; **p<0.01; ***p< 0.001; ****p< 0.0001).
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FIGURE 6. i.LN. injection of depots drives antigen-specific T cell responses locally in LNs and systemically in the periphery. (a)
Percentage and (b) numbers of SIINFEKL-tetramer+ CD8+ T cells in LNs at 1, 3 and 7 days after i.LN injection of PolyIC MP/OVA
depots or a PBS sham injection. Numbers are counted in an identical acquisition volume (80 lL). n = 9–10 LNs per group with bars
depicting mean 6 SEM. (**p< 0.01; ***p< 0.001) Mice were immunized i.LN. with PolyIC MP/OVA depots, Empty MPs, a sham
injection of PBS or left untreated (naı¨ve), and leukocytes from peripheral blood were stained for SIINFEKL-tetramer+ CD8+ T cells
weekly starting 7 days after immunization. Representative flow cytometry plots illustrating the gating scheme for SIINFEKL tet-
ramer staining of untreated mice (c), mice immunized i.LN. with a sham injection of PBS (d), Empty MPs (e), or PolyIC MP/OVA
depots (f) 7 days after treatment. (g) Mean percentage of SIINFEKL-tetramer positive T cells and (h) percentage of SIINFEKL
positive T cells with effector (CD62Llow/CD44high) or memory phenotypes (CD62Lhigh/CD44high) in mice from treatment groups
detailed in (c–f). n = 8 mice for Day 0, n = 10 mice per group at Day 7, and n = 4–5 mice per group for Days 14–28. (*p <
0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001).
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boost injections), peripheral blood was drawn and
MHC-I tetramer staining was used to quantify the
percentage of antigen speciﬁc CD8+ T cells (Trp2
tetramer for Trp2 immunized mice, SIINFEKL tetra-
mer for OVA immunized mice). For mice immunized
with OVA vaccine depots both treatments induced
very potent antigen-speciﬁc responses, but no signiﬁ-
cant differences were measured between responses in-
duced by CpG MPs and PolyIC MPs at either day
(Fig. 7, left). However, in mice treated with Trp2
vaccine depots, a signiﬁcantly higher level of Trp2
speciﬁc CD8+ T cells was observed in mice immunized
with CpG depots compared to PolyIC depots at both
time points (Fig. 7, right).
Local administration of CpG particles promotes anti-
tumor immunity
We next used an aggressive melanoma model—B16-
F10—to test the functionality of anti-tumor immunity
induced by vaccine depots administered by the i.LN.
route. Since vaccine depots formulated with CpG
promoted superior expansion of Trp2-speciﬁc cyto-
toxic T lymphocytes (CTLs) compared with PolyIC
(Fig. 7), we immunized mice with CpG depots con-
taining 3.5 lg of CpG and suspended in either Trp2, or
another conserved melanoma antigen, hgp100.28,35 In
these studies, mice were primed on day 0 with either
CpG MP/tumor antigen, or as a potent benchmark,
50 lg CpG and tumor antigen emulsiﬁed in mon-
tanide, one of the strongest adjuvants currently under
study.27,54 Animals were then boosted on day 15 with
identical doses and formulations, but all injections
were administered s.c. as a heterologous prime-boost
regimen. MHC-I tetramer staining for either Trp2- or
hgp100-speciﬁc CD8+ T cells revealed formulations
containing CpG MPs exhibited signiﬁcant increases in
these populations relative to other groups after both
priming and booster injections (Figs. 8a and 8b). After
a second boost on day 36, mice were challenged with
B16-F10 metastatic melanoma by implantation of
3 9 105 cells s.c. at the hind ﬂank. Compared to the
untreated group (Figs. 8c and 8h), the mice primed s.c.
with montanide/CpG/hgp100 (Figs. 8d and 8h) or
i.LN. with CpG MPs/hgp100 (Figs. 8f and 8h) did not
exhibit any therapeutic gains. In contrast, i.LN
immunization with CpG MP/Trp2 slowed tumor
growth, resulting in 40% survival at day 20 (Figs. 8g
and 8h), while all untreated mice succumbed by this
day (Figs. 8c and 8h). Interestingly, while Montanide/
CpG/Trp2 prolonged survival of mice to 29 days after
tumor challenge (Figs. 8e and 8h) the effect appeared
less potent than those generated by CpG MP/Trp2
vaccine regimens, which survived for up to 35 days.
The mean survival was 23.0 ± 4.5 days for the CpG
MP/Trp2 treated group, compared to 20.0 ± 2.4 days
for the Montanide/CpG/Trp2 treated group, and
16.3 ± 1.7 days for the untreated group, further
demonstrating the ability of local LN treatment to
promote functional, systemic immunity.
DISCUSSION
Biomaterials oﬀer a robust platform to co-deliver
immune signals, target vaccines to speciﬁc tissues, and
control delivery kinetics. However, most vaccines have
FIGURE 7. CpG MPs induce superior tumor-specific CTL
responses compared to PolyIC MPs. Mice were primed at day
0 i.LN. will either PolyIC MPs or CpG MPs, and either a model
antigen (OVA) or a melanoma associated antigen (Trp2) in a
soluble form. Mice were boosted at day 21, and antigen-
specific MHC-I tetramer was used to measure antigen specific
CD8+ T cell responses compared to a sham injection. (a)
7 days after priming, PolyIC and CpG MPs both induced po-
tent levels of SIINFEKL-specific CD8+, but no differences were
observed as a function of TLRa. In the Trp2 model, both
PolyIC and CpG MPs increased the levels of Trp2-specific
CD8+ T-cells, with CpG exhibiting a statistically significant
increase compared to both the sham and PolyIC MP injec-
tions. (b) At day 28, 7 days after the boost, a similar response
was seen with a robust response in the OVA model for both
PolyIC and CpG MPs, but without dependence on the specific
TLRa included in the particles. In the Trp2 studies, only CpG
MPs induced a significant, potent recall response. (*p< 0.05;
**p< 0.01; ***p< 0.001; ****p< 0.0001).
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complex formulations with multiple components, and
understanding how each component inﬂuences the
immune response alone or together has been chal-
lenging thus far. Previous research has shown that
altering material properties can inﬂuence and improve
the targeting of vaccines to LNs through lymphatic
drainage or traﬃcking within speciﬁc APCs after
internalization.20,30,40,41,49 i.LN. delivery, however, of-
fers a unique opportunity to directly study how the
form and combination of signals that ultimately reach
LNs impact immune response without the complexities
that occur after vaccines are administered by tradi-
tional routes. For example, even efﬁcacious vaccines
only result in a small fraction of the injected dose
reaching the LN and spleen—as little as 0.1%, whereas
pre-clinical and clinical trials studying i.LN. delivery of
FIGURE 8. i.LN. injection of CpG MP/Trp2 depots promote functional anti-tumor immunity. (a) Mice were left untreated, immu-
nized s.c. with Montanide/CpG/Trp2, or immunized i.LN. with CpG MP/Trp2, followed by s.c. boosts consisting of identical treat-
ments at Day 15. Trp2-tetramer specific T cells were quantified in peripheral blood at 6, 14 and 21 days after immunization. (b) A
study conducted using identical treatment regimens as in (a), but including an additional tumor antigen, hgp100. hgp100-specific
CD8+ T cell responses in peripheral blood were quantified using hgp100 MHC-I tetramer in peripheral blood at 6, 14 and 21 days
after immunization. Values indicate mean 6 SEM. (**p< 0.01; ***p< 0.001; ****p<0.0001 between CpG MP groups and naı¨ve;
##p<0.01; ###p< 0.001; ####p< 0.0001 between CpG MP groups and montanide). (c–h) Mice were left untreated, immunized with
Montanide/CpG/hgp100, Montanide/CpG/Trp2, CpG MP/hgp100 (i.LN.), or CpG MP/Trp2 (i.LN.) followed by s.c. boosts at Day 15 and
Day 36 as described in the methods. 43 days after the priming injection, mice were challenged with B16-F10 melanoma. Individual
tumor traces of untreated mice (c), mice immunized with Montanide/CpG/hgp100 (d), Montanide/CpG/Trp2 (e), CpG MP/hgp100 (f)
and CpG MP/Trp2 (g). (h) Percent survival of mice in the groups shown in (c–g).
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soluble vaccines have demonstrated dose-sparing fac-
tors as high as 106 relative to common peripheral
injection routes.23,45,53 With respect to nanoparticles,
past studies have revealed that particles administered
along common peripheral routes drain to LNs most
efﬁciently when the diameters are in the range of 20-
30 nm, whereas even 100 nm particles drain an order
of magnitude less efﬁciently.42 MP drainage relies
heavily on APC trafﬁcking.2 Our own past ﬁndings
demonstrate that improved retention of adjuvant in
LNs achieved by encapsulation in MPs too large to
freely drain from LNs after i.LN. injection drives very
strong T cell responses compared to equivalent doses
of soluble adjuvant administered i.LN., or adjuvant
MPs administered peripherally (e.g., in muscle).22 In
contrast, nanoparticles or soluble adjuvant are re-
tained in LNs at intermediate and low levels, respec-
tively, driving correspondingly lower responses relative
to MPs.22 Thus, here we used i.LN. injection of MPs to
add new understanding of how these local treatments
alter LN function over time, and how this local evo-
lution impacts systemic immunity.
With respect to local changes in LNs, several of our
ﬁndings together suggest an adjuvant mechanism
underpinned by increased activation of LN-resident
APCs. First, we generally observed large diﬀerence in
the number of immune cells in treated nodes relative to
sham injections, with more modest diﬀerences in the
relative cell compositions. These frequencies—for both
innate and adaptive immune cells—were similar to
those previously reported in LNs of C57BL6 mice.34
Second, we observed persistence of ﬂuorescent MPs for
at least 4 weeks (Fig. 1b), and increased activation of
LN-resident APCs (e.g., macrophages, DCs) as soon as
1 day after injection. Thus, one important role for the
depots appears to be enhanced local APC function that
could help increase lymphocyte proliferation and
inﬁltration. The resulting antigen-speciﬁc responses
showed enhancements consistent with strong T cell
response. For example, OVA-speciﬁc T cells developed
locally in LN over 7 days, by which time a dramatic
increase was measured in peripheral blood. This evo-
lution is consistent with primed lymphocytes migrating
out of the LNs as they expand against SIINFEKL
presented in these sites.56 Similarly, a shift towards a
central memory phenotype and away from effector
response was also observed over time, a goal for
effective vaccines.39 Interestingly, we did observe that
both depots and sham injections caused mod-
est—sometimes, transient—increases in the frequency
of B cells and CD4+ T cells. Thus, an additional
enhancing mechanism could be mild inﬂammation
caused by injection that, for example, could upregulate
adhesion molecules (e.g., P-, E-selectin) to better retain
circulating T and B cells. The absence of toxicity, and
the intact follicular structure of LNs after either sham
or adjuvant MP treatment, further supports the com-
patibility of this strategy for fundamental or applied
uses.
The link between the kinetics of vaccine dosing and
induction of immune response is well established, with
elegant studies demonstrating that increasing dosing
regimens drive synergistic immune responses more
eﬀectively than equivalent doses administered in a
bolus or at evenly spaced equal doses.24 This discovery
supports the basic premise for delivery of controlled
release depots to LNs, as the local dose of vaccine
components locally increases in LNs as cargo is re-
leased from degrading polymer particles.22 Further,
while there is signiﬁcant potential made possible by
determining whether vaccine particles loaded with
antigen, adjuvant, or both might be most potent for a
particular vaccine,26 design of adjuvant-loaded parti-
cles offer the appeal of ‘‘plug-n-play’’ vaccination
whereby the particle is simply mixed with a soluble
adjuvant of interest.
We found i.LN. injection of adjuvant MPs drove
antigen-speciﬁc T cell responses against both model
antigen (i.e., OVA) and tumor-associated antigens (i.e.,
Trp2, gp100) mixed with the depots. Interestingly, for
OVA, both PolyIC-loaded and CpG-loaded depots
performed equivalently, while CpG was more effective
in generating responses against tumor-associated
antigens. CpG has stimulated great interested in pre-
clinical cancer studies owing to effective priming of
CTL response.11,12,21,31,49 Thus, we benchmarked i.LN.
delivery of CpG MPs mixed with common conserved
melanoma antigens, against these same antigens
emulsiﬁed with CpG and montanide, one of the
strongest vaccine formulations under study.27,54 With
respect to both tumor-speciﬁc T cell expansion and
anti-tumor immunity, i.LN. depots were superior to
montanide, but interestingly, the dose of CpG in MP
formulations (3.5 lg/LN) was 14-fold lower than the
50 lg dose of CpG emulsiﬁed in the montanide vac-
cines. Thus, although the efﬁcacy achieved with i.LN.
depots in this study was modest (~40% of mice
exhibited signiﬁcantly increased survival), the en-
hanced performance compared with montanide and
this dose-sparing supports the potential of future MP-
based vaccines administered to LNs.
There are some considerations that might account
for the limited eﬃcacy observed in tumor challenge
studies. First, the chosen melanoma model is highly
aggressive. Second, general features of the tumor
microenvironment likely limit immunogenicity,
including suppression and antigen editing that prevents
tumor-speciﬁc CTLs from maintaining function or
recognizing antigens in tumors.33,44 Third, in our
experiments, we observed much higher frequencies of
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SIINFEKL-speciﬁc T cell responses after a single i.LN.
immunization with OVA depots relative to either
melanoma antigen, even after the latter were admin-
istered in several booster injections. OVA is a foreign
antigen, whereas Trp2 and hgp100 are self-antigens
and typically much less immunogenic. Since cross-
presentation of minimal epitope peptides such as Trp2
and hgp100—can enhance immunogenicity,16,18,29,32
encapsulation of antigen in MPs alone, or in con-
junction with adjuvant might offer one route to further
improve potency. However, since signiﬁcant popula-
tions of antigen-speciﬁc CD8+ T cells were generated
against either tumor antigen, we speculate more robust
responses might improve effectiveness. Along these
lines, recent pre-clinical and clinical studies reveal
simultaneously activating multiple TLR pathways
during cancer therapy can enhance therapeutic efﬁ-
cacy,1,5,13,52 suggesting another strategy based on
loading of MPs with multiple TLRas.
i.LN. delivery of MPs also provides some unique
opportunities to impact the tumor microenvironment
through appropriate selection of the LN for injection.
In our studies we selected the inguinal LN for ease of
injection based on our past work, and what has been
used in recent human trials involving i.LN. delivery of
soluble tumor antigens to inguinal LNs.43 However,
this technique could also be used to target tumor
draining lymph nodes (TDLN), sites which have re-
cently been shown to be effective for passive targeting of
cancer vaccines.9,10,20,49 Remarkably, several landmark
studies also demonstrate that both anti-tumor T cells
and regulatory T cells (TREGs)—cells that suppress anti-
tumor response in tumors—are primed in the same
LN.8,17 Thus, direct LN targeting of TDLNs might al-
low local polarization toward effector cells while also
reducing suppressive TREGs that play an important role
in maintaining the suppressive tumor microenviron-
ment. This may further provide an opportunity to
effectively combat tumors without affecting natural
regulatory activity in other distant LNs. It is also pos-
sible that targeting TDLNs is not necessary if optimized
particles expand tumor-speciﬁc cells that are able to
migrate to tumors, but further studies will be needed to
investigate this possibility. Finally, creating opportu-
nities to overcome the suppressive characteristics of
tumors by directly targeting the TDLN, or pairing with
exciting new immunotherapies such as checkpoint
blockades could also have offer signiﬁcant potential for
cancer vaccination.36,46
CONCLUSION
i.LN. injection allows direct control over the dose
and combinations of materials administered to LNs,
supporting a new approach for studying the impact of
vaccines on the LN microenvironment. Here, we
demonstrate that a single i.LN. injection can lead to
dramatic local changes in these tissues, increasing the
number and function of both APCs and lymphocytes.
The local changes result in systemic, but antigen-
speciﬁc pro-immune function that provides functional
anti-tumor immunity in a melanoma model. Thus, this
approach might hold clinical utility for vaccines based
on intra-LN controlled release of antigens and adju-
vants, while also providing a strategy to evaluate the
immunogenicity of biomaterial carriers themselves, or
to design carriers loaded with deﬁned combinations of
antigens and adjuvants.
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